Judit OlÃ;h

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3578672/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nature Communications, 2015, 6, 6263.	5.8	222
2	Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). Journal of Medicinal Chemistry, 2018, 61, 482-491.	2.9	204
3	Interactions of Pathological Hallmark Proteins. Journal of Biological Chemistry, 2011, 286, 34088-34100.	1.6	138
4	Triosephosphate isomerase deficiency: New insights into an enigmatic disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 1168-1174.	1.8	126
5	Brain-Specific p25 Protein Binds to Tubulin and Microtubules and Induces Aberrant Microtubule Assemblies at Substoichiometric Concentrations. Biochemistry, 2002, 41, 8657-8664.	1.2	121
6	Triosephosphate isomerase deficiency: Facts and doubts. IUBMB Life, 2006, 58, 703-715.	1.5	101
7	TPPP/p25 Promotes Tubulin Acetylation by Inhibiting Histone Deacetylase 6. Journal of Biological Chemistry, 2010, 285, 17896-17906.	1.6	91
8	Tubulin Polymerization Promoting Proteins (TPPPs):Â Members of a New Family with Distinct Structures and Functionsâ€. Biochemistry, 2006, 45, 13818-13826.	1.2	83
9	Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure–Activity Relationship Study. Journal of Medicinal Chemistry, 2016, 59, 1599-1612.	2.9	76
10	Tubulin polymerization promoting protein (TPPP/p25) as a marker for oligodendroglial changes in multiple sclerosis. Glia, 2010, 58, 1847-1857.	2.5	61
11	Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS Journal, 2008, 275, 4740-4755.	2.2	60
12	Triosephosphate isomerase deficiency: a neurodegenerative misfolding disease. Biochemical Society Transactions, 2002, 30, 30-38.	1.6	50
13	Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels. Biochemical Journal, 2005, 392, 675-683.	1.7	40
14	Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Letters, 2006, 580, 5807-5814.	1.3	34
15	Disordered TPPP/p25 binds GTP and displays Mg ²⁺ -dependent GTPase activity. FEBS Letters, 2011, 585, 803-808.	1.3	26
16	Synthesis and in Vitro Antitumor Effect of Vinblastine Derivativeâ^'Oligoarginine Conjugates. Bioconjugate Chemistry, 2010, 21, 1948-1955.	1.8	25
17	Zn ²⁺ -Induced Rearrangement of the Disordered TPPP/p25 Affects Its Microtubule Assembly and GTPase Activity. Biochemistry, 2011, 50, 9568-9578.	1.2	25
18	Identification of motives mediating alternative functions of the neomorphic moonlighting TPPP/p25. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 547-557.	1.8	25

Judit OlÃih

#	Article	IF	CITATIONS
19	Challenging drug target for Parkinson's disease: Pathological complex of the chameleon TPPP/p25 and alpha-synuclein proteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 310-323.	1.8	23
20	Microtubule-Associated Proteins with Regulatory Functions by Day and Pathological Potency at Night. Cells, 2020, 9, 357.	1.8	23
21	Phosphoenolpyruvate-dependent Tubulin-Pyruvate Kinase Interaction at Different Organizational Levels. Journal of Biological Chemistry, 2003, 278, 7126-7130.	1.6	22
22	A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. Biochemical and Biophysical Research Communications, 2011, 409, 137-141.	1.0	22
23	Targeting the interface of the pathological complex of α-synuclein and TPPP/p25. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2653-2661.	1.8	18
24	Tubulin Binding and Polymerization Promoting Properties of Tubulin Polymerization Promoting Proteins Are Evolutionarily Conserved. Biochemistry, 2017, 56, 1017-1024.	1.2	18
25	Role of the microtubule-associated TPPP/p25 in Parkinson's and related diseases and its therapeutic potential. Expert Review of Proteomics, 2017, 14, 301-309.	1.3	18
26	Modulation Of Microtubule Acetylation By The Interplay Of TPPP/p25, SIRT2 And New Anticancer Agents With Anti-SIRT2 Potency. Scientific Reports, 2017, 7, 17070.	1.6	17
27	Challenges in Discovering Drugs That Target the Protein–Protein Interactions of Disordered Proteins. International Journal of Molecular Sciences, 2022, 23, 1550.	1.8	16
28	HaloTagâ€Targeted Sirtuinâ€Rearranging Ligand (SirReal) for the Development of Proteolysisâ€Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)**. ChemBioChem, 2020, 21, 3371-3376.	1.3	13
29	Microtubule assembly-derived by dimerization of TPPP/p25. Evaluation of thermodynamic parameters for multiple equilibrium system from ITC data. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 785-794.	1.1	12
30	Dual life of TPPP/p25 evolved in physiological and pathological conditions. Biochemical Society Transactions, 2014, 42, 1762-1767.	1.6	11
31	Pharmacological targeting of αâ€synuclein and TPPP /p25 in Parkinson's disease: challenges and opportunities in a Nutshell. FEBS Letters, 2019, 593, 1641-1653.	1.3	11
32	Zinc-induced structural changes of the disordered tppp/p25 inhibits its degradation by the proteasome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 83-91.	1.8	9
33	Co-Transmission of Alpha-Synuclein and TPPP/p25 Inhibits Their Proteolytic Degradation in Human Cell Models. Frontiers in Molecular Biosciences, 2021, 8, 666026.	1.6	9
34	Reappraisal of triosephosphate isomerase deficiency. European Journal of Haematology, 2011, 86, 265-267.	1.1	5
35	TPPP/p25: A New Unstructured Protein Hallmarking Synucleinopathies. Focus on Structural Biology, 2009, , 225-250.	0.1	5
36	Modeling of sensing potency of cytoskeletal systems decorated with metabolic enzymes. Journal of Theoretical Biology, 2015, 365, 190-196.	0.8	4

Judit OlÃih

		15	Currenter
#	ARTICLE	IF	CITATIONS
37	Localization of the zinc binding tubulin polymerization promoting protein in the mice and human eye. Journal of Trace Elements in Medicine and Biology, 2018, 49, 222-230.	1.5	4
38	Interactions between two regulatory proteins of microtubule dynamics, HDAC6, TPPP/p25, and the hub protein, DYNLL/LC8. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 118556.	1.9	4
39	A Potential Innovative Therapy for Parkinson's Disease: Selective Destruction of the Pathological Assemblies of Alpha-Synuclein. , 0, , .		3
40	Anti-Aggregative Effect of the Antioxidant DJ-1 on the TPPP/p25-Derived Pathological Associations of Alpha-Synuclein. Cells, 2021, 10, 2909.	1.8	1